Cargando…
Harnessing Lactate Metabolism for Radiosensitization
Cancer cells rewire their metabolism to promote cell proliferation, invasion, and metastasis. Alterations in the lactate pathway have been characterized in diverse cancers, correlate with outcomes, and lead to many downstream effects, including decreasing oxidative stress, promoting an immunosuppres...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343095/ https://www.ncbi.nlm.nih.gov/pubmed/34367959 http://dx.doi.org/10.3389/fonc.2021.672339 |
_version_ | 1783734204414033920 |
---|---|
author | Liu, Kevin X. Everdell, Emily Pal, Sharmistha Haas-Kogan, Daphne A. Milligan, Michael G. |
author_facet | Liu, Kevin X. Everdell, Emily Pal, Sharmistha Haas-Kogan, Daphne A. Milligan, Michael G. |
author_sort | Liu, Kevin X. |
collection | PubMed |
description | Cancer cells rewire their metabolism to promote cell proliferation, invasion, and metastasis. Alterations in the lactate pathway have been characterized in diverse cancers, correlate with outcomes, and lead to many downstream effects, including decreasing oxidative stress, promoting an immunosuppressive tumor microenvironment, lipid synthesis, and building chemo- or radio-resistance. Radiotherapy is a key modality of treatment for many cancers and approximately 50% of patients with cancer will receive radiation for cure or palliation; thus, overcoming radio-resistance is important for improving outcomes. Growing research suggests that important molecular controls of the lactate pathway may serve as novel therapeutic targets and in particular, radiosensitizers. In this mini-review, we will provide an overview of lactate metabolism in cancer, discuss three important contributors to lactate metabolism (lactate dehydrogenase, monocarboxylate transporters, and mitochondrial pyruvate carrier), and present data that inhibition of these three pathways can lead to radiosensitization. Future research is needed to further understand critical regulators of lactate metabolism and explore clinical safety and efficacy of inhibitors of lactate dehydrogenase, monocarboxylate transporters, and mitochondrial pyruvate carrier alone and in combination with radiation. |
format | Online Article Text |
id | pubmed-8343095 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83430952021-08-07 Harnessing Lactate Metabolism for Radiosensitization Liu, Kevin X. Everdell, Emily Pal, Sharmistha Haas-Kogan, Daphne A. Milligan, Michael G. Front Oncol Oncology Cancer cells rewire their metabolism to promote cell proliferation, invasion, and metastasis. Alterations in the lactate pathway have been characterized in diverse cancers, correlate with outcomes, and lead to many downstream effects, including decreasing oxidative stress, promoting an immunosuppressive tumor microenvironment, lipid synthesis, and building chemo- or radio-resistance. Radiotherapy is a key modality of treatment for many cancers and approximately 50% of patients with cancer will receive radiation for cure or palliation; thus, overcoming radio-resistance is important for improving outcomes. Growing research suggests that important molecular controls of the lactate pathway may serve as novel therapeutic targets and in particular, radiosensitizers. In this mini-review, we will provide an overview of lactate metabolism in cancer, discuss three important contributors to lactate metabolism (lactate dehydrogenase, monocarboxylate transporters, and mitochondrial pyruvate carrier), and present data that inhibition of these three pathways can lead to radiosensitization. Future research is needed to further understand critical regulators of lactate metabolism and explore clinical safety and efficacy of inhibitors of lactate dehydrogenase, monocarboxylate transporters, and mitochondrial pyruvate carrier alone and in combination with radiation. Frontiers Media S.A. 2021-07-23 /pmc/articles/PMC8343095/ /pubmed/34367959 http://dx.doi.org/10.3389/fonc.2021.672339 Text en Copyright © 2021 Liu, Everdell, Pal, Haas-Kogan and Milligan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Liu, Kevin X. Everdell, Emily Pal, Sharmistha Haas-Kogan, Daphne A. Milligan, Michael G. Harnessing Lactate Metabolism for Radiosensitization |
title | Harnessing Lactate Metabolism for Radiosensitization |
title_full | Harnessing Lactate Metabolism for Radiosensitization |
title_fullStr | Harnessing Lactate Metabolism for Radiosensitization |
title_full_unstemmed | Harnessing Lactate Metabolism for Radiosensitization |
title_short | Harnessing Lactate Metabolism for Radiosensitization |
title_sort | harnessing lactate metabolism for radiosensitization |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343095/ https://www.ncbi.nlm.nih.gov/pubmed/34367959 http://dx.doi.org/10.3389/fonc.2021.672339 |
work_keys_str_mv | AT liukevinx harnessinglactatemetabolismforradiosensitization AT everdellemily harnessinglactatemetabolismforradiosensitization AT palsharmistha harnessinglactatemetabolismforradiosensitization AT haaskogandaphnea harnessinglactatemetabolismforradiosensitization AT milliganmichaelg harnessinglactatemetabolismforradiosensitization |